sgRNA-shRNA Structure Mediated SNP Site Editing on Porcine IGF2 Gene by CRISPR/StCas9
The SNP within intron 3 of the porcine gene (G3072A) plays an important role for muscle growth and fat deposition in pigs. In this study, the StCas9 derived from together with the Drosha-mediated sgRNA-shRNA structure were combined to boost the G to A base editing on the SNP site, which we called &q...
Saved in:
Published in | Frontiers in genetics Vol. 10; p. 347 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
18.04.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The SNP within intron 3 of the porcine
gene (G3072A) plays an important role for muscle growth and fat deposition in pigs. In this study, the StCas9 derived from
together with the Drosha-mediated sgRNA-shRNA structure were combined to boost the G to A base editing on the
SNP site, which we called "SNP editing." The codon-humanized StCas9 as we previously reported was firstly compared with the prevalently used SpCas9 derived from
using our idiomatic surrogate report assay, and the StCas9 demonstrated a comparable targeting activity. On the other hand, by combining shRNA with sgRNA, simultaneous gene silencing and genome targeting can be achieved. Thus, the novel IGF2.sgRNA-LIG4.shRNA-IGF2.sgRNA structure was constructed to enhance the sgRNA/Cas9-mediated HDR-based
SNP editing by silencing the
gene, which is a key molecule of the HDR's competitive NHEJ pathway. The sgRNA-shRNA/StCas9 all-in-one expression vector and the IGF2.sgRNA/StCas9 as control were separately used to transfect porcine PK15 cells together with an ssODNs donor for the
SNP editing. The editing events were detected by the RFLP assay, Sanger sequencing as well as Deep-sequencing, and the Deep-sequencing results finally demonstrated a significant higher HDR-based editing efficiency (16.38%) for our sgRNA-shRNA/StCas9 strategy. In short, we achieved effective
SNP editing by using the combined sgRNA-shRNA/StCas9 strategy, which will facilitate the further production of base-edited animals and perhaps extend for the gene therapy for the base correction of some genetic diseases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Youri I. Pavlov, University of Nebraska Medical Center, United States Reviewed by: Claudio Mussolino, Institut für Zell- und Gentherapie (IZG), Germany; Magdy Mahfouz, King Abdullah University of Science and Technology, Saudi Arabia These authors have contributed equally to this work This article was submitted to Genomic Assay Technology, a section of the journal Frontiers in Genetics |
ISSN: | 1664-8021 1664-8021 |
DOI: | 10.3389/fgene.2019.00347 |